Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists.

Zhong M, Shen W, Barr KJ, Arbitrario JP, Arkin MR, Bui M, Chen T, Cunningham BC, Evanchik MJ, Hanan EJ, Hoch U, Huen K, Hyde J, Kumer JL, Lac T, Lawrence CE, Martell JR, Oslob JD, Paulvannan K, Prabhu S, Silverman JA, Wright J, Yu CH, Zhu J, Flanagan WM.

Bioorg Med Chem Lett. 2010 Sep 1;20(17):5269-73. doi: 10.1016/j.bmcl.2010.06.145. Epub 2010 Jul 23.

PMID:
20655213
2.

Small-molecule inhibition of TNF-alpha.

He MM, Smith AS, Oslob JD, Flanagan WM, Braisted AC, Whitty A, Cancilla MT, Wang J, Lugovskoy AA, Yoburn JC, Fung AD, Farrington G, Eldredge JK, Day ES, Cruz LA, Cachero TG, Miller SK, Friedman JE, Choong IC, Cunningham BC.

Science. 2005 Nov 11;310(5750):1022-5.

3.

De novo design of an IL-4 antagonist and its structure at 1.9 A.

Laporte SL, Forsyth CM, Cunningham BC, Miercke LJ, Akhavan D, Stroud RM.

Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1889-94. Epub 2005 Jan 31.

4.

Phage display for selection of novel binding peptides.

Sidhu SS, Lowman HB, Cunningham BC, Wells JA.

Methods Enzymol. 2000;328:333-63. No abstract available.

PMID:
11075354
5.

Crystal structure of the complex between VEGF and a receptor-blocking peptide.

Wiesmann C, Christinger HW, Cochran AG, Cunningham BC, Fairbrother WJ, Keenan CJ, Meng G, de Vos AM.

Biochemistry. 1998 Dec 22;37(51):17765-72.

PMID:
9922142
6.

Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site.

Fairbrother WJ, Christinger HW, Cochran AG, Fuh G, Keenan CJ, Quan C, Shriver SK, Tom JY, Wells JA, Cunningham BC.

Biochemistry. 1998 Dec 22;37(51):17754-64.

PMID:
9922141
7.

Growth hormone binding affinity for its receptor surpasses the requirements for cellular activity.

Pearce KH Jr, Cunningham BC, Fuh G, Teeri T, Wells JA.

Biochemistry. 1999 Jan 5;38(1):81-9.

PMID:
9890885
8.

VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface.

Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB, de Vos AM.

Structure. 1998 Sep 15;6(9):1153-67.

9.

Minimized proteins.

Cunningham BC, Wells JA.

Curr Opin Struct Biol. 1997 Aug;7(4):457-62. Review.

PMID:
9266165
10.

Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site.

Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de Vos AM.

Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7192-7.

11.

Crystallization of the receptor binding domain of vascular endothelial growth factor.

Christinger HW, Muller YA, Berleau LT, Keyt BA, Cunningham BC, Ferrara N, de Vos AM.

Proteins. 1996 Nov;26(3):353-7.

PMID:
8953654
12.

Recombinant human growth hormone (GH)-binding protein enhances the growth-promoting activity of human GH in the rat.

Clark RG, Mortensen DL, Carlsson LM, Spencer SA, McKay P, Mulkerrin M, Moore J, Cunningham BC.

Endocrinology. 1996 Oct;137(10):4308-15.

PMID:
8828490
13.

Impact of the Human Genome Project at the interface between patent and FDA laws.

Cunningham BC.

Risk. 1996 Summer;7(3):253-66. No abstract available.

PMID:
11655078
14.

Minimization of a polypeptide hormone.

Li B, Tom JY, Oare D, Yen R, Fairbrother WJ, Wells JA, Cunningham BC.

Science. 1995 Dec 8;270(5242):1657-60.

PMID:
7502074
15.

Solution conformation of an atrial natriuretic peptide variant selective for the type A receptor.

Fairbrother WJ, McDowell RS, Cunningham BC.

Biochemistry. 1994 Aug 2;33(30):8897-904.

PMID:
8043577
16.

Production of an atrial natriuretic peptide variant that is specific for type A receptor.

Cunningham BC, Lowe DG, Li B, Bennett BD, Wells JA.

EMBO J. 1994 Jun 1;13(11):2508-15.

17.

Comparison of a structural and a functional epitope.

Cunningham BC, Wells JA.

J Mol Biol. 1993 Dec 5;234(3):554-63. Erratum in: J Mol Biol 1994 Apr 8;237(4):513.

PMID:
7504735
18.

Evidence that the growth hormone receptor mediates differentiation and development of the mammary gland.

Feldman M, Ruan W, Cunningham BC, Wells JA, Kleinberg DL.

Endocrinology. 1993 Oct;133(4):1602-8.

PMID:
8404600
19.

The molecular basis for growth hormone-receptor interactions.

Wells JA, Cunningham BC, Fuh G, Lowman HB, Bass SH, Mulkerrin MG, Ultsch M, deVos AM.

Recent Prog Horm Res. 1993;48:253-75. Review.

PMID:
8441850
20.

Immunodominant structures of human growth hormone identified by homolog-scanning mutagenesis.

Weber JR, Nelson C, Cunningham BC, Wells JA, Fong S.

Mol Immunol. 1992 Sep;29(9):1081-8.

PMID:
1495498
21.

Rational design of potent antagonists to the human growth hormone receptor.

Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA.

Science. 1992 Jun 19;256(5064):1677-80.

PMID:
1535167
22.

Growth hormone augments superoxide anion secretion of human neutrophils by binding to the prolactin receptor.

Fu YK, Arkins S, Fuh G, Cunningham BC, Wells JA, Fong S, Cronin MJ, Dantzer R, Kelley KW.

J Clin Invest. 1992 Feb;89(2):451-7.

23.

Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule.

Cunningham BC, Ultsch M, De Vos AM, Mulkerrin MG, Clauser KR, Wells JA.

Science. 1991 Nov 8;254(5033):821-5.

PMID:
1948064
24.

Dimerization of human growth hormone by zinc.

Cunningham BC, Mulkerrin MG, Wells JA.

Science. 1991 Aug 2;253(5019):545-8.

PMID:
1907025
25.

Mutational analysis and protein engineering of receptor-binding determinants in human placental lactogen.

Lowman HB, Cunningham BC, Wells JA.

J Biol Chem. 1991 Jun 15;266(17):10982-8.

26.

Rational design of receptor-specific variants of human growth hormone.

Cunningham BC, Wells JA.

Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3407-11.

27.

Zinc mediation of the binding of human growth hormone to the human prolactin receptor.

Cunningham BC, Bass S, Fuh G, Wells JA.

Science. 1990 Dec 21;250(4988):1709-12.

PMID:
2270485
28.

Engineering human prolactin to bind to the human growth hormone receptor.

Cunningham BC, Henner DJ, Wells JA.

Science. 1990 Mar 23;247(4949 Pt 1):1461-5.

PMID:
2321008
29.

Identification and design of binding determinants in proteins.

Wells JA, Cunningham BC.

Biochem Soc Symp. 1990;57:143-5.

PMID:
2099738
30.

High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis.

Cunningham BC, Wells JA.

Science. 1989 Jun 2;244(4908):1081-5.

PMID:
2471267
31.

Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis.

Cunningham BC, Jhurani P, Ng P, Wells JA.

Science. 1989 Mar 10;243(4896):1330-6.

PMID:
2466339
32.
33.

Recruitment of substrate-specificity properties from one enzyme into a related one by protein engineering.

Wells JA, Cunningham BC, Graycar TP, Estell DA.

Proc Natl Acad Sci U S A. 1987 Aug;84(15):5167-71.

34.

On the evolution of specificity and catalysis in subtilisin.

Wells JA, Cunningham BC, Graycar TP, Estell DA, Carter P.

Cold Spring Harb Symp Quant Biol. 1987;52:647-52. No abstract available.

PMID:
3331349

Supplemental Content

Loading ...
Support Center